A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.

[1]  A. Emamifar,et al.  Use of a Mandatory Declination Form in a Program for Influenza Vaccination of Healthcare Workers , 2008, Infection Control & Hospital Epidemiology.

[2]  R. Couch,et al.  A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. , 2007, Vaccine.

[3]  J. Langley,et al.  Safety and immunogenicity of a Proteosome -trivalent inactivated influenza vaccine, given nasally to healthy adults. , 2006, Vaccine.

[4]  J. Treanor,et al.  Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. , 2006, Vaccine.

[5]  D. Simel,et al.  Does This Patient Have Influenza? , 2006, Annals of Emergency Medicine.

[6]  J. Oxford,et al.  FluINsure™, an inactivated trivalent influenza vaccine for intranasal administration, is protective in human challenge with A/Panama/2007/99 (H3N2) virus , 2004 .

[7]  J. Langley,et al.  An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Update: statement on influenza vaccination for the 2003-04 season. , 2004, Canada communicable disease report = Releve des maladies transmissibles au Canada.

[8]  M. Bergeron,et al.  Multiplex Real-Time PCR Assay for Detection of Influenza and Human Respiratory Syncytial Viruses , 2004, Journal of Clinical Microbiology.

[9]  M. Thobaben,et al.  Prevention and Control of Influenza , 2003, MMWR. Morbidity and mortality weekly report.

[10]  D. Fleming,et al.  Multiplex reverse transcription-PCR for surveillance of influenza A and B viruses in England and Wales in 1995 and 1996 , 1997, Journal of clinical microbiology.

[11]  G L Ada,et al.  Options for the control of influenza III. Cairns, North Queensland, Australia (4-9 May 1996). , 1997, Vaccine.

[12]  J. Eyles,et al.  Intranasal Administration of Influenza Vaccines , 2012, BioDrugs.

[13]  N. Cox,et al.  Prevention and Control of Influenza Recommendations of the Advisory Committee on Immunization Practices ( ACIP ) , 2007 , 2007 .

[14]  J. Abramowitz,et al.  Fear of needles and vasovagal reactions among phlebotomy patients. , 2006, Journal of anxiety disorders.

[15]  N. Cox,et al.  Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[16]  Influenza in Canada: 2003-2004 season. , 2005, Canada communicable disease report = Releve des maladies transmissibles au Canada.

[17]  J. Eyles,et al.  Intranasal administration of influenza vaccines: current status. , 2000, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[18]  T. Jefferson,et al.  Vaccines for preventing influenza in healthy adults. , 2000, The Cochrane database of systematic reviews.